ARIBIO Counts On Multi-Modal Drug For Alzheimer's And Vascular Dementia

ARIBIO CEO tells Scrip how the South Korean biotech is aiming to develop a multi-modal drug for both Alzheimer’s disease and vascular dementia using its innovative platform technology, which can cut development periods and costs and better predict clinical trial success.

Matthew Choung
ARIBIO CEO Matthew Jai Jun Choung Says Paradigm Shift Needed For Dementia Drug Development • Source: ARIBIO

Amid continued failures in clinical trials of new drugs for Alzheimer’s disease (AD), researchers are beginning to have doubts about whether the "one drug, one target" paradigm is the way to go.

Biogen Inc./Eisai Co. Ltd.'s BACE inhibitor elenbecestat has just become the latest late-stage failure in the field, after showing an unfavorable risk-benefit ratio

More from South Korea

More from Focus On Asia